title: Selection criteria for complete cytoreduction after cytoreductive surgery for peritoneal surface malignancy: lessons learned from our first series of patients.
abstract: The appropriate selection criteria for complete cytoreduction in patients with peritoneal surface malignancies have not been determined. We performed a retrospective analysis of all patients receiving cytoreductive surgery (CRS) during the study period of 2004 to 2008 to determine appropriate selection criteria for successful complete cytoreduction. During the study period, 38 patients underwent attempted CRS. Cytoreduction was scored complete, incomplete, or not reported in 53 per cent (n = 20), 37 per cent (n = 14), and 11 per cent (n = 4), respectively. Median overall survival for compete and incomplete cytoreduction was 56 months versus 5 months (P = 0.011), respectively. Compared with incomplete cytoreduction, patients receiving complete cytoreduction were more likely to have a lower Peritoneal Cancer Index (PCI) and not have received preoperative systemic chemotherapy (CT). Univariate analysis verified PCI greater than 20 (hazard ratio [HR], 0.048; CI, 0.004 to 0.515; P = 0.01) and CT (HR, 0.17; 0.004 to 0.77; P = 0.021) as predictors of incomplete cytoreduction. Small bowel (100%), periportal region (33%), and mesentery (27%) were the most common sites of residual disease. In conclusion, PCI less than 20 and the need for preoperative chemotherapy should be strongly considered when selecting patients with peritoneal surface malignancy for attempted cytoreduction. Early evaluation of the small bowel, mesentery, and periportal region for resectability prevents unnecessary surgery.
authors.affiliation: Departments of General Oncologic Surgery, City of Hope National Medical Center, Duarte, California 91010-3000, USA. smckenzie@coh.org
authors.forename: Shaun
authors.initials: S
authors.lastname: McKenzie
authors.forename: Avo
authors.initials: A
authors.lastname: Artinyan
authors.forename: Alicia D
authors.initials: AD
authors.lastname: Holt
authors.forename: Julio
authors.initials: J
authors.lastname: Garcia-Aguilar
authors.forename: Joshua
authors.initials: J
authors.lastname: Ellenhorn
authors.forename: Robert
authors.initials: R
authors.lastname: Morgan
authors.forename: Benjamin
authors.initials: B
authors.lastname: Paz
mesh_terms: D002140:California; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual; D018579:Patient Selection; D010534:Peritoneal Neoplasms / Q000473:pathology* / Q000601:surgery*; D011183:Postoperative Complications / Q000517:prevention & control; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome